Hydrothorax fluid microparticle metabolite combination, kit and method for diagnosing tuberculous pleurisy

Abstract

The invention relates to a hydrothorax microparticle metabolite combination, a kit and a method for diagnosing tuberculous pleurisy. The pleural effusion microparticle metabolite composition for diagnosing tuberculous pleurisy comprises phenylalanine, tyrosine, methionine, kynurenine, lauroyl carnitine, glycine-binding chenodeoxycholic acid, phosphatidylcholine with the ratio of 36: 7 and lysophosphatidylcholine with the ratio of 20: 2. The kit for diagnosing tuberculous pleurisy comprises an internal standard substance for detecting the concentration of metabolites in the pleural effusion microparticle sample extraction solution. A combined marker provided by the invention has the characteristics of high sensitivity and high specificity for the diagnosis of tuberculous pleurisy, at the same time, can be complementary with a traditional marker adenosine deaminase, and can be used for the auxiliary diagnosis of the tuberculous pleurisy by being combined with the traditional marker adenosine deaminase.

Description

technical field [0001] The invention relates to a tuberculous diagnosis method, in particular to a pleural effusion microparticle metabolite combination, a kit and a method for diagnosing tuberculous pleurisy. Background technique [0002] Tuberculous pleurisy is a common clinical extrapulmonary tuberculosis with a relatively high incidence, accounting for about 44.1% of the total pleural diseases. In my country, the incidence of malignant pleurisy is as high as 900,000 per year, accounting for about 9% of the world's total. The morbidity and mortality rate of lung cancer is one of the highest tumors in the world, and about 40% of lung cancer patients will have malignant pleural effusion during the disease process. At present, due to the limitations of diagnostic techniques, the proportion of confirmed cases is very low. However, the prognosis and treatment of tuberculous pleurisy and malignant pleurisy are completely different. If not diagnosed and treated in time, it will...

AI Technical Summary

Problems solved by technology

[0003] At present, the methods for clinical diagnosis and identification of tuberculous pleurisy and malignant pleurisy include clinical manifestations, thoracentesis test results, pleural biopsy, bronchoscopy, surgical biopsy, etc. The most commonly used method is thoracentesis for cytological examination. Tumor cells found in pleural effusion have diagnostic value for malignant pleurisy, but due to the complex cell components in pleural effusion, it is sometimes difficult to distinguish tumor cells from inflammatory mesothelial cells, macrophages, etc. Influenced by other factors, its sensitivity is low (about 40%-60%), and the disadvantages of strong subjectivit

Images